ガンにおけるタンパク質アルギニンメチルトランスファーゼ (PRMTs) を標的とする現在および新興の治療法

Adriana Kaganovski¹, Bayle Smith-Salzberg¹, Hadar K Shimshon¹

¹College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA.

International journal of molecular sciences

|August 28, 2025

まとめ

タンパク質アルギニンメチルトランスフェラーゼ (PRMT) は遺伝子発現と細胞過程を調節する. このレビューは,PRMTsを強調しています.

科学分野:

エピジェネティクスと分子生物学
癌研究
薬理学について

背景:

タンパク質アルギニンメチルトランスフェラーゼ (PRMTs) は,アルギニンのメチル化を触媒する酵素であり,これは翻訳後の重要な変化である.
PRMTsは遺伝子発現,信号伝達,細胞増殖に影響を与える表遺伝子調節剤として機能する.
異常なPRMT活動は,乳がん,肺がん,大腸がんを含む様々ながんの進行に関与しており,しばしば予後不良と相関しています.

研究の目的:

癌の発生と進行における個々のPRMTsの特定の役割を検討する.
潜在的治療薬としてPRMT阻害剤の開発における最近の進歩を強調する.
腫瘍学におけるPRMTsの治療の可能性を強調する.

主な方法:

癌におけるPRMTsに関する臨床前および臨床研究の包括的な文献レビュー.
様々ながんのPRMTsの調節不全に関する研究の分析
新型PRMT阻害剤の有効性と治療の可能性の評価

主要な成果:

PRMTsは癌において様々な役割を果たし,その調節不良は腫瘍発生に寄与する.
PRMTの活性を標的とする多数の新薬は,臨床前および臨床試験で重要な治療効果を示した.
PRMTの過剰発現は,複数の癌の患者による悪影響と関連しています.

結論:

PRMTsはがんの重要なレギュレータであり治療のターゲットとして有望です
新興のPRMT阻害剤は,がん治療の有意な可能性を示しています.
腫瘍学におけるPRMTsの治療的有用性を完全に解明するには,さらなる研究が不可欠です.

キーワード:

PRMT について PRMT1 について PRMT2 について PRMT3 について PRMT4 について PRMT5 について PRMT6 について PRMT7 について PRMT8 について PRMT9 について

さらに関連する動画

08:11

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Published on: August 7, 2021

4.3K

10:01

In vitro Methylation Assay to Study Protein Arginine Methylation

Published on: October 5, 2014

15.4K

関連する概念動画

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.8K

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

2.8K

03:03

mTOR Signaling and Cancer Progression

3.9K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

3.9K

02:38

Mitogens and the Cell Cycle

6.6K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

6.6K

01:27

Tumor Immunotherapy

659

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

659

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...